We agree that further study of the long-term effects of β-blockers in patients with reactive airway disease is needed. Our study demonstrated the safety of cardioselective β-blockers in patients with mild to moderate reactive airway disease who were followed for up to 4 weeks. We believe that this study paves the way for larger, long-term trials to be done. In the meta-analysis, patients who received a single dose or continued treatment with a cardioselective β-blocker had an increased FEV1 response to β-agonists compared with placebo. Furthermore, in the continued treatment trials, steroid use, asthma exacerbations, and hospitalizations did not increase.